Entera Bio Ltd (NASDAQ:ENTX) — Market Cap & Net Worth
Market Cap & Net Worth: Entera Bio Ltd (ENTX)
Entera Bio Ltd (NASDAQ:ENTX) has a market capitalization of $64.20 Million ($64.20 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20853 globally and #4645 in its home market, demonstrating a 40.38% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Entera Bio Ltd's stock price $2.99 by its total outstanding shares 45857242 (45.86 Million). Review debt load of Entera Bio Ltd to assess the company's total debt and financial obligations.
Entera Bio Ltd Market Cap History: 2018 to 2026
Entera Bio Ltd's market capitalization history from 2018 to 2026. Data shows change from $139.86 Million to $137.11 Million (-8.76% CAGR).
Index Memberships
Entera Bio Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #594 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #2001 of 3165 |
Weight: Entera Bio Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Entera Bio Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Entera Bio Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
537.11x
Entera Bio Ltd's market cap is 537.11 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $139.86 Million | $500.00K | -$10.30 Million | 279.73x | N/A |
| 2019 | $98.13 Million | $236.00K | -$10.79 Million | 415.82x | N/A |
| 2020 | $49.53 Million | $365.00K | -$9.98 Million | 135.69x | N/A |
| 2021 | $129.09 Million | $571.00K | -$12.19 Million | 226.07x | N/A |
| 2022 | $33.48 Million | $134.00K | -$13.07 Million | 249.82x | N/A |
| 2023 | $27.51 Million | $14.00K | -$8.89 Million | 1965.31x | N/A |
| 2024 | $97.22 Million | $181.00K | -$9.54 Million | 537.11x | N/A |
Competitor Companies of ENTX by Market Capitalization
Companies near Entera Bio Ltd in the global market cap rankings as of August 3, 2026.
Key companies related to Entera Bio Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Entera Bio Ltd Historical Marketcap From 2018 to 2026
Between 2018 and today, Entera Bio Ltd's market cap moved from $139.86 Million to $ 137.11 Million, with a yearly change of -8.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $137.11 Million | +54.12% |
| 2025 | $88.96 Million | -8.49% |
| 2024 | $97.22 Million | +253.33% |
| 2023 | $27.51 Million | -17.81% |
| 2022 | $33.48 Million | -74.07% |
| 2021 | $129.09 Million | +160.65% |
| 2020 | $49.53 Million | -49.53% |
| 2019 | $98.13 Million | -29.84% |
| 2018 | $139.86 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Entera Bio Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $64.20 Million USD |
| MoneyControl | $64.20 Million USD |
| MarketWatch | $64.20 Million USD |
| marketcap.company | $64.20 Million USD |
| Reuters | $64.20 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Entera Bio Ltd
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial … Read more